Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-08-03 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2023年度向特定对象发行股票摊薄即期回报与填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific stock issuance to particular investors by Beijing Northland Biotech Co., Ltd. It discusses the dilution impact on immediate returns, financial assumptions, risk warnings, necessity and rationality of the issuance, investment projects, and commitments by controlling shareholders and management. The document includes financial projections and detailed explanations about the capital raising and its effects on financial metrics such as earnings per share and net asset return rate. It is not a full annual or interim report but a specific update on capital raising and related measures. The document length is 8929 characters, which is substantial and contains substantive financial data and analysis related to the capital issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-08-03 Chinese
第六届监事会第三次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of the resolutions passed at the third meeting of the sixth supervisory board of Beijing Northland Biotech Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results. The main content revolves around adjustments to the company's 2023 private placement of shares, including changes to the fundraising amount and the use of proceeds. The document does not contain financial statements or detailed financial analysis but rather reports on decisions made by the supervisory board regarding capital raising activities. It is an official announcement related to capital raising and financing activities, specifically adjustments to a private placement plan. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3156 characters, which is sufficient to contain substantive content rather than a mere announcement of a report publication. Hence, it is not an RPA or RNS filing.
2023-08-03 Chinese
2023年度向特定对象发行股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for the use of funds raised through a specific stock issuance by Beijing Northland Biotechnology Co., Ltd. in 2023. It includes extensive financial figures, project descriptions, investment plans, and regulatory approvals related to the use of the raised capital. The content focuses on the company's capital raising and the planned allocation of those funds to various projects, including drug development and new drug industrialization. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and project investment data, not merely an announcement or certification. Therefore, it is not a report publication announcement or regulatory filing. It is not an annual or interim report, nor an earnings release, nor a management or governance report. The primary focus is on the use of proceeds from a specific stock issuance, fitting the CAP category.
2023-08-03 Chinese
第六届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth board of directors' third meeting of Beijing Northland Biotechnology Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and specific decisions such as adjustments to a private placement of shares, capital increase due to stock option exercises, and a loan application. The content focuses on board-level decisions and approvals rather than financial results, audit opinions, or shareholder voting outcomes. There is no indication that this is a full annual or interim report, earnings release, or regulatory filing of financial data. The document is not a proxy statement or AGM materials but rather a formal announcement of board meeting resolutions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4670 characters) and detailed content support this classification with high confidence.
2023-08-03 Chinese
关于调减公司 2023 年度向特定对象发行股票募集资金总额暨调整发行方案的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the total amount of funds to be raised through a specific private placement of shares in 2023 by Beijing Northland Biotech Co., Ltd. It details the changes in the fundraising amount and the allocation of proceeds, including project investments and repayment of bank loans. The document also mentions the approval process by the board and shareholders and the need for regulatory approval before implementation. The content focuses on capital raising activities and changes to the issuance plan rather than presenting financial statements or results. The document length is short (1814 characters) and is an announcement of a financing plan adjustment, not a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-03 Chinese
股权激励计划预留部分股票期权行权结果公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the exercise of reserved stock options under an equity incentive plan by Beijing Northland Biotechnology Co., Ltd. It details the number of shares exercised, the participants, changes in shareholding, and the impact on the company's capital structure. It includes specific data on share quantities, exercise prices, and changes in ownership percentages. The document is not a full financial report but a specific update on share capital changes due to stock option exercises. This fits the category of Share Issue/Capital Change announcements, as it reports on new shares issued upon option exercise and changes in capital structure. The document length is 2519 characters, which is relatively short but contains detailed data on share capital changes, not just a brief notice or a report publication announcement. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2023-07-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.